Five stories that shaped payment integrity in July, and what each one means for payers and vendors.
CMS deferred $1.07B in California and Minnesota Medicaid payments on July 21 pending documentation audits, and its Medicaid Fraud War Room separately reported stopping more than $203M in its first 88 days. Both states are contesting the deferrals.
What it means
For payers. CMS is shifting its emphasis toward pre-payment enforcement. Programs weighted toward post-payment recovery may want to reassess against that shift.
For vendors. Demand is shifting toward pre-payment tooling. Vendors who can show RADV-ready audit infrastructure and pre-payment detection are positioned for both the regulatory and the political environment.
CMS's provider-tax and state-directed-payment rules would cut Medicaid spending by an estimated $774.8B over ten years, capping directed payments at Medicare rates with a phase-down from 2028. Virginia already projects $31B in losses, and other large states are running the same math.
What it means
For payers. Directed-payment cuts are likely to drive network renegotiation, and tightening margins tend to pull audit demand up. Model the phase-down into rate and network strategy now.
For vendors. As hospital Medicaid revenue contracts, billing-optimization pressure and audit volume climb. The states and service lines most dependent on directed payments are where PI demand rises first.
HHS-OIG's semiannual report to Congress reported $5.56B in expected recoveries and savings for the six months through March, and $12.70 returned for every dollar it spent. Two managed care settlements carried much of the managed-care total: Kaiser Permanente affiliates at $556M and CVS Health's Aetna at $117.7M, both resolving allegations of inflated Medicare Advantage risk-adjustment billing. DOJ has named MA fraud its top enforcement priority for 2026, even as OIG's overall enforcement pipeline narrowed, with exclusions down to 1,212 from about 1,500 a year earlier.
What it means
For payers. Risk-adjustment coding is now a balance-sheet risk, not only a compliance question. The Kaiser and Aetna figures set the benchmark regulators and whistleblowers will measure against, so audit your diagnosis-code and chart-review practices now.
For vendors. Risk-adjustment validation is where the enforcement pressure concentrates. Plans will pay for tooling that can defend a diagnosis code, and RADV-ready validation moves from useful to expected.
No Surprises Act arbitration awards in 2025, about six times in-network rates. CMS issued its first public "may be gamed" admission.
CMS's July release puts 2025 No Surprises Act arbitration awards at $15B, roughly six times typical in-network rates per the Wall Street Journal. Providers win about 85 percent of determinations, 90 percent land above the benchmark, and three entities drive about 44 percent of filings. CMS made its first public admission that the process may be gamed.
What it means
For payers. The filing concentration is a dispute-defense roadmap. With a handful of entities driving most volume and most disputes ineligible, pre-submission eligibility screening against those filers is where the return is highest.
For vendors. No major PI vendor has formally entered IDR audit and defense, which leaves the fastest-growing dispute channel largely uncovered.
Two bipartisan bills advanced fast, House Energy and Commerce 45-0 and Senate HELP 21-1. Medicare Advantage plans would have to publicly disclose prior-authorization volume, denial rates, and timing, with CEO certification of price accuracy behind it.
What it means
For payers. MA prior-auth disclosure looks near-certain, and public denial-rate reporting invites outside scrutiny. Defensible, documented denials become a requirement.
For vendors. Explainable denial documentation is now a product-roadmap signal. Tools that can show their work on every denial become a requirement rather than a differentiator.
Where to find us
The Throughline lands monthly. Get the next issue delivered to your inbox, and find us on LinkedIn between issues.
The Throughline: PI Monthly is a public-domain market-watching publication. It does not contain proprietary vendor assessments, client program intelligence, or competitive scoring. For tailored intelligence, contact us directly.
Browse all issues →